TEL AVIV, Israel, June 11, 2018 /PRNewswire/ -- Therapix
Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a
specialty, clinical-stage pharmaceutical company focusing on the
development of cannabinoid-based treatments, announces sponsorship
of the 11th European Society for the Study of
Tourette Syndrome (ESSTS) conference, in Copenhagen Denmark, on June 13th until June 15th, as part of the Company's
strategy to develop therapy for Tourette's patients and to support
the Tourette's community.
The European Society for the Study of Tourette Syndrome
(ESSTS), aims to coordinate pan-European efforts for the study of
Gilles de la Tourette Syndrome (TS) and associated disorders and
provide a platform for global outreach and educational
activities. The annual meeting draws doctors and researchers
from all over the world, and this year will honor Dr. Michael H. Bloch, M.D., as a keynote speaker to
present Therapix's Phase IIa study results in Tourette Syndrome.
Dr. Bloch, an Associate Professor at the Yale
University Child Study Center, the investigator-initiator of
the trial, and a member of the Company's scientific advisory board
committee.
The study, suggesting that the proprietary cannabinoid
combination THX-110 [which is a combination of dronabinol
(∆-9-tetrahydracannabinol) and palmitoylethanolamide (PEA)] showed
significantly improved symptoms over time in adult subjects with
Tourette syndrome (link to press release). The study was led
together with James F. Leckman,
M.D., Ph.D., of the Neison Harris Professor in the Child Study
Center and Professor of Pediatrics Child Psychiatry at Yale University.
Dr. Ascher Shmulewitz, M.D.,
Ph.D, Therapix's chairman and CEO said: "We are happy to take part
in the efforts to find a cure for Tourette's Syndrome, while our
proprietary drug is being evaluated in clinical trials, we wish to
support the research and community for this unmet need".
About Therapix Biosciences:
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of Senior
Executives and Scientists. Our focus is creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in the following drug development programs based on repurposing an
FDA-approved cannabinoid (Dronabinol): THX-110 for the treatment of
Tourette syndrome (TS), for the treatment of Obstructive Sleep
Apnea (OSA), and the treatment of Pain; THX-130 for the treatment
of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury
(TBI); THX-150 for the treatment of infectious diseases; and
THX-160 for the treatment of pain. Please visit our website for
more information at www.therapixbio.com
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Because such statements deal with future events
and are based on Therapix's current expectations, they are subject
to various risks and uncertainties and actual results, performance
or achievements of Therapix could differ materially from those
described in or implied by the statements in this press release.
For example, forward-looking statements include statements
regarding the Company's plans with respect to its clinical trials
and its intent to report material developments and information
regarding such trials. In addition, historic results of scientific
research and clinical and preclinical trials do not guarantee that
the conclusions of future research or trials will suggest identical
or even similar conclusions. The forward-looking statements
contained or implied in this press release are subject to other
risks and uncertainties, including those discussed under the
heading "Risk Factors" in Therapix Biosciences Ltd.'s Annual Report
on Form 20-F filed with the Securities and Exchange Commission
(SEC) on April 30, 2018 and in
subsequent filings with the SEC. Except as otherwise required by
law, Therapix disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date they were made, whether as a result of new information, future
events or circumstances or otherwise.
Investor Contact
Suzanne Lyons
Suzanne@therapixbio.com
Media Contact
Sydney Masters
Sydney@MastersMallory.com
M: 917-584-8385
P: 212-987-6804
View original
content:http://www.prnewswire.com/news-releases/therapix-biosciences-sponsors-the-2018-annual-meeting-of-the-european-society-for-the-study-of-tourette-syndrome-300664379.html
SOURCE Therapix Biosciences Ltd.